December 19, 2012—The biotechnology company Amgen agreed today to a $762 million global settlement with the federal government that encompasses claims that the company knowingly misreported best prices and average manufacturer prices (AMPs) for several of its drugs.
A federal district judge in Brooklyn, N.Y., accepted a guilty plea by Amgen for illegally introducing a misbranded drug, Aranesp, into interstate commerce.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)